BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 8406188)

  • 1. Consolidation intraperitoneal chemotherapy in epithelial ovarian cancer patients following negative second-look laparotomy.
    Tarraza HM; Boyce CR; Smith WG; Jones MA
    Gynecol Oncol; 1993 Sep; 50(3):287-90. PubMed ID: 8406188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intraperitoneal mitoxantrone as consolidation treatment for stage III ovarian carcinoma: a pilot study.
    Dufour P; Maloisel F; Bergerat JP; Barats JC; Dellenbach P; Renaud R; Ritter P; Herbrecht R; Wendling C; Audhuy B
    Bull Cancer; 1991; 78(3):273-80. PubMed ID: 2054526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous chemotherapy, early debulking surgery, and consolidation intraperitoneal chemotherapy in advanced ovarian carcinoma.
    Tournigand C; Louvet C; Molitor JL; Dehni N; Lejeune V; Sezeur A; Pigne A; Marpeau L; Cady J; de Gramont A
    Gynecol Oncol; 2001 Nov; 83(2):198-204. PubMed ID: 11606072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of intraperitoneal cisplatin and mitoxantrone in patients with persistent ovarian cancer.
    Husain A; Sabbatini P; Spriggs D; Fennelly D; Aghajanian C; Barakat R; Curtin J; Venkatraman E; Hoskins W; Markman M
    Gynecol Oncol; 1999 Apr; 73(1):96-101. PubMed ID: 10094887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intraperitoneal cisplatin and intravenous paclitaxel in the treatment of epithelial ovarian cancer patients with a positive second look.
    Makhija S; Sabbatini P; Aghajanian C; Venkatraman E; Spriggs DR; Barakat R
    Gynecol Oncol; 2000 Oct; 79(1):28-32. PubMed ID: 11006026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II trial of intraperitoneal cisplatin and etoposide as consolidation therapy in patients with Stage II-IV epithelial ovarian cancer following negative surgical assessment.
    Barakat RR; Almadrones L; Venkatraman ES; Aghajanian C; Brown C; Shapiro F; Curtin JP; Spriggs D
    Gynecol Oncol; 1998 Apr; 69(1):17-22. PubMed ID: 9570993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second line platinum-based intraperitoneal chemotherapy for advanced ovarian cancer.
    Milczek T; Klasa-Mazurkiewicz D; Emerich J; Kobierski J
    Acta Obstet Gynecol Scand; 2009; 88(4):463-7. PubMed ID: 19235559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intraperitoneal mitoxantrone or floxuridine: effects on time-to-failure and survival in patients with minimal residual ovarian cancer after second-look laparotomy--a randomized phase II study by theSouthwest Oncology Group.
    Muggia FM; Liu PY; Alberts DS; Wallace DL; O'Toole RV; Terada KY; Franklin EW; Herrer GW; Goldberg DA; Hannigan EV
    Gynecol Oncol; 1996 Jun; 61(3):395-402. PubMed ID: 8641622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologico Nord-Ovest.
    Gadducci A; Carnino F; Chiara S; Brunetti I; Tanganelli L; Romanini A; Bruzzone M; Conte PF
    Gynecol Oncol; 2000 Feb; 76(2):157-62. PubMed ID: 10637064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intraperitoneal mitoxantrone as consolidation treatment for patients with ovarian carcinoma in pathologic complete remission.
    Dufour P; Bergerat JP; Barats JC; Giron C; Duclos B; Dellenbach P; Ritter J; Renaud R; Audhuy B; Oberling F
    Cancer; 1994 Apr; 73(7):1865-9. PubMed ID: 8137212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of combination intraperitoneal cisplatin and 5-fluorouracil in previously treated patients with advanced ovarian cancer: long-term follow-up.
    Morgan RJ; Braly P; Leong L; Shibata S; Margolin K; Somlo G; McNamara M; Longmate J; Schinke S; Raschko J; Nagasawa S; Kogut N; Najera L; Johnson D; Doroshow JH
    Gynecol Oncol; 2000 Jun; 77(3):433-8. PubMed ID: 10831355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II study of intraperitoneal cisplatin and thiotepa in residual ovarian carcinoma: a Gynecologic Oncology Group study.
    Feun LG; Blessing JA; Major FJ; DiSaia PJ; Alvarez RD; Berek JS
    Gynecol Oncol; 1998 Dec; 71(3):410-5. PubMed ID: 9887240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cisplatin and cyclophosphamide in early epithelial ovarian carcinoma.
    Chiara S; Conte PF; Bruzzone M; Falcone A; Sertoli MR; Carnino F; Mossetti C; Iura R; Durando C; Guercio E
    Chemioterapia; 1987 Oct; 6(5):380-3. PubMed ID: 3427698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-intensity intravenous cyclophosphamide and cisplatin, interim surgical debulking, and intraperitoneal cisplatin in advanced ovarian carcinoma: a pilot trial with ten-year follow-up.
    Shapiro F; Schneider J; Markman M; Reichman BS; Venkatraman E; Barakat R; Almadrones L; Spriggs D
    Gynecol Oncol; 1997 Oct; 67(1):39-45. PubMed ID: 9345354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Results of intraperitoneal chemotherapy of ovarian cancer].
    de Gramont A; Marpeau L; Demuynck B; Louvet C; Varette C; Gonzalez-Canali G; Pigné A; Herbulot P; Lagadec B; Cady J
    J Gynecol Obstet Biol Reprod (Paris); 1991; 20(3):387-92. PubMed ID: 1869784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of an intraperitoneal chemotherapy program implemented at the Princess Margaret Hospital for patients with epithelial ovarian carcinoma.
    Chin SN; Pinto V; Rosen B; Oza A; Dodge J; Murphy J; Mackay H
    Gynecol Oncol; 2009 Mar; 112(3):450-4. PubMed ID: 19135709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Intraperitoneal high dose chemotherapy as consolidation treatment for advanced ovarian carcinoma: a pilot study].
    Gladieff L; Chatelut E; Gaspard MH; Skaf R; de Forni M; Mihura J; Canal P; Bugat R
    Bull Cancer; 1999; 86(7-8):673-7. PubMed ID: 10477384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toxicity of abdominopelvic radiation in advanced ovarian carcinoma patients after cisplatin/cyclophosphamide therapy and second-look laparotomy.
    Shelley WE; Starreveld AA; Carmichael JA; O'Connell G; Roy M; Swenerton K
    Obstet Gynecol; 1988 Mar; 71(3 Pt 1):327-32. PubMed ID: 3347416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gynecological malignancies.
    Schaebler DL; Schilder RJ; Young RC
    Cancer Chemother Biol Response Modif; 1996; 16():564-91. PubMed ID: 8639401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of intraperitoneal cisplatin with intravenous doxorubicin and cyclophosphamide in previously untreated patients with advanced ovarian cancer-long-term follow-up.
    Morgan RJ; Braly P; Cecchi G; Leong L; Shibata S; Margolin K; Somlo G; McNamara M; Longmate J; Schinke S; Raschko J; Nagasawa S; Kogut N; Parker P; Stein A; Cho J; Smith E; Coluzzi P; Najera L; Johnson D; Womack E; Doroshow JH
    Gynecol Oncol; 1999 Dec; 75(3):419-26. PubMed ID: 10600300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.